Counterfeit packages of the irritable bowel syndrome medication Coloverin-D are circulating in the market, according to a warning issued by the Medical Supplies and Equipment Department at the Ministry of Health in Benghazi. The alert stems from Fraud Bulletin No. 62 of 2026 published by the Egyptian Drug Authority, which identified falsified versions of the product bearing batch number A251035.
Official Warning on Coloverin-D Batch A251035
Health authorities are urging all hospitals, medical centers, clinics, and pharmacies to immediately check their inventory for the affected medication. According to the Medical Supplies and Equipment Department, any packages matching batch number A251035 should not be distributed or used under any circumstances. Healthcare providers must verify the exact source of all medical supplies before dispensing treatments to patients.
Did you know? Counterfeit medications often replicate the outer packaging closely, making batch number verification through official fraud bulletins one of the most reliable ways to catch falsified drugs before they reach patients.
Steps for Healthcare Providers and Pharmacies
The Ministry of Health directive mandates strict vigilance across the entire supply chain. Facilities are instructed to report any suspected counterfeit or non-compliant drugs immediately. By tracing the origin of every shipment, medical professionals can prevent compromised gastrointestinal treatments from harming vulnerable patients.
Pro Tips for Verifying Pharmaceutical Safety
Frequently Asked Questions
What product is affected by the recent health warning?
Counterfeit packages of Coloverin-D, a medication primarily used to treat irritable bowel syndrome and gastrointestinal cramps, have been flagged by regulators.
Which batch number is identified as counterfeit?
According to Fraud Bulletin No. 62 of 2026 issued by the Egyptian Drug Authority, the falsified packages carry batch number A251035.
What should medical facilities do if they find the affected batch?
Hospitals, clinics, and pharmacies must refrain from distributing or using the medication and immediately report the suspected counterfeit drugs to the Ministry of Health.
Keep reading